Changes to Intermediary Metabolites in Sporadic and <i>LRRK2</i> Parkinson’s Disease Demonstrated by Proton Magnetic Resonance Spectroscopy

<div>Proton magnetic resonance (<sup>1</sup>H-MR) spectrum of cerebrospinal fluid from a<i> LRRK2</i> p.G2019S-PD patient (HOB: hydroxybutyrate, HOIB: hydroxyisobutyrate).</div>

Parkinson’s Disease

fig1

Figure 1

Figure 1: Changes to Intermediary Metabolites in Sporadic and <i>LRRK2</i> Parkinson’s Disease Demonstrated by Proton Magnetic Resonance Spectroscopy 

Parkinson’s Disease

Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson’s Disease Demonstrated by Proton Magnetic Resonance Spectroscopy

Figure 1